133 related articles for article (PubMed ID: 33215504)
1. Safety of High-Dose Unfractionated Heparin for Prophylaxis of Venous Thromboembolism in Hospitalized Obese Patients.
Regis T; Goriacko P; Ferguson N
Ann Pharmacother; 2021 Aug; 55(8):963-969. PubMed ID: 33215504
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients.
Joy M; Tharp E; Hartman H; Schepcoff S; Cortes J; Sieg A; Mariski M; Lee Y; Murphy M; Ranjbar G; Sharaf S; Yau G; Choi HA; Samuel S
Pharmacotherapy; 2016 Jul; 36(7):740-8. PubMed ID: 27265806
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
Mason SW; Barber A; Jones E; Chen SL; Moll S; Northam K
Am J Med; 2020 Jun; 133(6):e249-e259. PubMed ID: 31862336
[TBL] [Abstract][Full Text] [Related]
4. Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
DeBiase C; Giuliano CA; Doshi M; Ganoff M; Alexander Paxton R
Pharmacotherapy; 2021 May; 41(5):424-429. PubMed ID: 33641194
[TBL] [Abstract][Full Text] [Related]
5. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
[TBL] [Abstract][Full Text] [Related]
6. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
Shlensky JA; Thurber KM; O'Meara JG; Ou NN; Osborn JL; Dierkhising RA; Mara KC; Bierle DM; Daniels PR
Vasc Med; 2020 Feb; 25(1):47-54. PubMed ID: 31623539
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Twice- Versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center.
Wiethorn EE; Harrison S; Weeda ER; Bell CM
Ann Pharmacother; 2022 May; 56(5):541-547. PubMed ID: 34459268
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of High-Dose Subcutaneous Unfractionated Heparin Prophylaxis for the Prevention of Venous Thromboembolism in Obese Hospitalized Patients.
Beall J; Woodruff A; Hempel C; Wovkulich M; Zammit K
Hosp Pharm; 2016 May; 51(5):376-81. PubMed ID: 27303091
[TBL] [Abstract][Full Text] [Related]
9. Varying Dosages of Subcutaneous Unfractionated Heparin and Activated Partial Thromboplastin Time in Hospitalized Antepartum Patients: A Retrospective Cohort Analysis.
Elmofty DH; Tucker A; Wuenstel AM; Cheng PK; Fox E; Knoebel R; Liao C; Scavone B
Anesth Analg; 2022 May; 134(5):1028-1034. PubMed ID: 35020621
[TBL] [Abstract][Full Text] [Related]
10. Emergency Department Management of Acute Venous Thromboembolism in Patients With Obesity With Intravenous Unfractionated Heparin and Anti-Xa Monitoring.
Tyler DJ; Caruso KA; Lyden AE; Karpowitsch KM
J Pharm Pract; 2023 Jun; 36(3):588-593. PubMed ID: 35113739
[No Abstract] [Full Text] [Related]
11. The effect of heparin infusion intensity on outcomes for bridging hospitalized patients with atrial fibrillation.
Warden BA; Diep C; Ran R; Thomas M; Cigarroa JE
Clin Cardiol; 2019 Oct; 42(10):995-1002. PubMed ID: 31483512
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically Ill patients.
Lee YR; Blanco DD
J Thromb Thrombolysis; 2017 Oct; 44(3):386-391. PubMed ID: 28828713
[TBL] [Abstract][Full Text] [Related]
14. Heparin dosing for venous thromboembolism prophylaxis in obese hospitalized patients: An observational study.
Patanwala AE; Seaman SM; Kopp BJ; Erstad BL
Thromb Res; 2018 Sep; 169():152-156. PubMed ID: 30071480
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose versus Therapeutic Range Intravenous Unfractionated Heparin Prophylaxis in the Treatment of Patients with Severe Aneurysmal Subarachnoid Hemorrhage After Aneurysm Occlusion.
Kunz M; Siller S; Nell C; Schniepp R; Dorn F; Huge V; Tonn JC; Pfister HW; Schichor C
World Neurosurg; 2018 Sep; 117():e705-e711. PubMed ID: 29959066
[TBL] [Abstract][Full Text] [Related]
16. Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation.
Thompson MH; Wilson SH; Toussaint BL; Jordan CL; Hayes GL; McKinzie BP; Wolf BJ; Field LC
J Clin Anesth; 2016 Sep; 33():346-50. PubMed ID: 27555191
[TBL] [Abstract][Full Text] [Related]
17. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
[TBL] [Abstract][Full Text] [Related]
18. Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.
Harrington DW
Hosp Pract (1995); 2010 Nov; 38(4):18-28. PubMed ID: 21068523
[TBL] [Abstract][Full Text] [Related]
19. Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: A randomized noninferiority trial.
Olson EJ; Bandle J; Calvo RY; Shackford SR; Dunne CE; Van Gent JM; Zander AL; Sikand H; Bongiovanni MS; Sise MJ; Sise CB
J Trauma Acute Care Surg; 2015 Dec; 79(6):961-8; discussion 968-9. PubMed ID: 26317819
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
